Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms AWAKE-HF
- Sponsors Novartis
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.
- 24 Nov 2016 New trial record